Drug Development Flashcards

1
Q

What is a DRUG LEAD?

A

A compound with a required biological response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Give problems with drug leads.

A
Too slow/fast
non-specific target
insoluble
poor metabolism
side effects
toxicity
difficult synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
Cheimcal modification stratergies 1:
Simplification- remove non-essential parts to improve target --- and remove ---/---.
Pharmacophore for cocaine and procaine:
The important --- groups are ---
The unnecessary --- group s removed.
The complex --- system is removed.
Also a need to remove --- centres.
Identify the more potent --- and refine the ---.
A
specificity
side-efffects
binding
retained
ester
ring
asymmetric
enantiomer
synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Structure rigidification:
Used to limit the number of —
incorporate adjacent groups to hinder —
incorporate a — substituent on to a —
Put the functional group into a — system

A
conformations
rotation
bulky
ring
ring
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Conversion of hydroxyl to ,ethyl ether or ester:

This alters - bonding, —/—, interactions between drug and —, activity and —

A

H
water solubility
target
bioavailability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Effects of the conversion of amine to amide:
Amines are more/less basic than amides?
The ionic activity is removed if it is —
This changes the bonding to the —, and also changes the – and the —

A
more
protonated
receptor
activity
bioavailability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Conversion of ketone to Alcohol:
The — is still present, but it is — different, Alcohols have a — bonding shape, and ketones have a — bonding shape.
This may change the —/—.

A
H-bonding
structurally
tetrahedral
planar
bonding site
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Removal of double bonds:
This changes the shape from planar to —
It reduces — interactions with the — pocket of the —

A

non-planar
van der Waals
hydrophobic
receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Alteration of alkyl size and introduction of unsaturation:
Branching, multiple bonds, aromatic rings have more — interactions with the —/— than —/—.
This may alter the — and — with a receptor, or alter the activity of the —

A
VDW
binding region
alkyl chains
docking
binding
enzyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Use of a steric shield:

This is where a — group or two —/— are added to prevent metabolic — or —

A

bulky
adjacent substituents
hydrolysis
oxidation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Altering chain length:
Chain extension may improve —/— or find secondary —/—. Raising n in (CH2)n will assist —/—, but in general, when n>6 , this generally prevents —/—.

A

primary bonding
bonding sites
membrane transport
aqueous transport

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Rings and substituents:
Extra rings or — are sometimes used to find another —/—
Expansion + contraction of ring alters relative position of —/—

A

heteroatoms
binding region
binding groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Configuration change at carbon:
Binding site may be sensitive to the — environment.
The Ea of of enzymic — may differ
enantiomers may — in vivo

A

chiral
intermediates
interconvert

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
Bioisosteres:
These are atoms or groups of atoms which are closely related in --- or --- which can be --- in a compound to produce similar --- properties.
F as an isostere of H:
This has an effect on --- and ---
The - withdrawing - affects its neighbours.
The altered -- changes the preferred ---
There is an improved metabolic ---
The metabolically active site is ---
A
size
charge
exchanged
biological
pKa
reactivity
e- 
F
H-bonding
conformation
stability
blocked
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Non-classical bioisosteres:

These are structurally —, there is usually a different number of — and exhibit different — and — properties

A

distinct
atoms
steric
electronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is a prodrug?

A

A pharmacologically inactive drug that can be converted to an active drug metabolic process in vivo.

17
Q

Latentiation:

A

Where the bioactivity is latent.

18
Q

Prodrugs should be readily — by an —, or react readily —
It should be less — than, and much less — than the active drug. It should not introduce toxic —
Hard drugs are compunds which…
Soft drugs are compounds which

A
metabolised
enzyme
biochemically
toxic
active
metabolites
are not susceptible to metabolism
are readily metabolised.
19
Q

Prodrug examples:
The most common strategy is to make an —
From a — and a —
It is converted to the — in vivo by —
Other groups that undergo phase I metabolism includes the — of the compound.
The antibacterial prodrug prontosil is converted to an active — by —/—

A
ester
alcohol
carboxylic acid
acid
esterases
deamination
sulphonamide 
azo reduction
20
Q

Prodrug examples- making it ionic:
This raises the —/— but leads to poorer — transport
The —/— reacts with a base to give an —/—
The secondary amine is generally more/less polar than the primary, it can be derivatized to a —/—/—.
Protonated tertiary amines are less — and have weaker — bonding to the target

A
water solubility
membrane
carboxylic acid
ionic salt
less
phopsphate disodium salt
basic
ionic
21
Q

Making polar drugs for carrier proteins:
L-Dopa has ability to cross the —/— barrier.
then — remove the — group so that dopamine can be delivered after the — has been crossed.

A

blood-brain
decarboxylases
CO2H
membrane

22
Q

Alkylate to improve membrane permeability:
Eg. the prodrug antihistamine terfenadine.
Metabolised in the — by — to convert one — to the active —/—

A

liver
cytochrome P450
CH3
carboxylic acid

23
Q
Prodrug strategies summary
Esterify a ---/---, or other groups undergoing a ---/---/---
Make --- drugs for --- proteins
Alkylate to improve ---/---
Prolong activity by (2)
Target the site by --- and ---
\:
A
carboxylic acid
phase 1 metabolism
polar
carrier
membrane permeability
ring addition or longer chain addition
pH, enzyme
24
Q

Sleeping drugs:
— prodrug activated by an — agent
Main research in development of —/—
— agents collect in —

A
inactive
external
photodynamic therapy
photosensitive
cells.